HCG Manavata Performs First PIPAC Surgery in Maharashtra for Advanced Abdominal Cancer

PIPAC offers potential advantages such as more localized therapy, improved drug efficacy, and shorter recovery periods.

HCG Manavata Cancer Centre (HCGMCC) in Nashik has conducted its first Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) surgery, marking a new development in treating advanced abdominal cancers in Maharashtra.

The procedure was performed on a patient with advanced stomach cancer, led by Dr Ninad Katdare of HCG Cancer Centre Mumbai, in collaboration with Prof Dr Raj Nagarkar, Managing Director and Chief of Surgical Oncology and Robotic Services at HCGMCC. 

PIPAC is a laparoscopic procedure that delivers chemotherapy as a pressurized aerosol directly into the peritoneal cavity. German surgeon Dr Marc Reymond first introduced it in the early 2000s and has gained global recognition for its role in managing peritoneal cancers originating from the stomach, ovaries, and colon.

“PIPAC represents a paradigm shift in how we approach advanced abdominal cancers. The breakthrough technique allows chemotherapy to be delivered directly into the peritoneal cavity in aerosolized form using laparoscopic access. The pressurized delivery improves drug penetration, allowing for targeted treatment with minimal systemic side effects. It not only maximizes the therapeutic effect of chemotherapy but also enhances patient comfort and recovery. This successful collaboration between our team at HCG Manavata and HCG Mumbai highlights the power of shared expertise,” said Prof Dr Raj Nagarkar.

Standard treatment options often result in limited clinical benefits for patients with peritoneal metastases. PIPAC offers potential advantages such as more localized therapy, improved drug efficacy, and shorter recovery periods. It may also be combined with other cancer treatments, including systemic chemotherapy, immunotherapy, or radiation.

“The ability to combine PIPAC with other modalities such as systemic chemotherapy and immunotherapy makes it a versatile tool in the oncological arsenal. As surgeons, our learning never ends and embracing new technologies like PIPAC ensures we can deliver the best to our patients. We’re excited about the promise it holds for patients with limited treatment options,” Dr Nagarkar added.

Established in 2007 by Dr Raj Nagarkar, HCGMCC is Central India's first NABH-accredited cancer facility. Based in Nashik, the centre employs over 50 consultant oncologists and 900 staff members and has a capacity of 275 beds. It provides surgical, radiation, and medical oncology services and has performed over 65,000 surgeries, including over 1,400 robotic-assisted procedures.

Stay tuned for more such updates on Digital Health News.

Stay tuned for more such updates on Digital Health News